Novo Research Development vs Ebit Analysis

NVO Stock

USD 105.06 2.43 2.37%

Novo Nordisk financial indicator trend analysis is infinitely more than just investigating Novo Nordisk AS recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Novo Nordisk AS is a good investment. Please check the relationship between Novo Nordisk Research Development and its Ebit accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

Research Development vs Ebit

Research Development vs Ebit Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Novo Nordisk AS Research Development account and Ebit. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Novo Nordisk's Research Development and Ebit is 0.98. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Ebit in the same time period over historical financial statements of Novo Nordisk AS, assuming nothing else is changed. The correlation between historical values of Novo Nordisk's Research Development and Ebit is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of Novo Nordisk AS are associated (or correlated) with its Ebit. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebit has no effect on the direction of Research Development i.e., Novo Nordisk's Research Development and Ebit go up and down completely randomly.

Correlation Coefficient

0.98

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Research Development

Ebit

Most indicators from Novo Nordisk's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Novo Nordisk AS current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

At this time, Novo Nordisk's Selling General Administrative is very stable compared to the past year. As of the 25th of November 2024, Sales General And Administrative To Revenue is likely to grow to 0.04, while Tax Provision is likely to drop about 12.8 B.

	2021	2022	2023	2024 (projected)
Gross Profit	117.1B	148.5B	196.5B	206.3B
Total Revenue	140.8B	177.0B	232.3B	243.9B

Gross Profit Total Revenue

Novo Nordisk fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Other Current Assets	Accounts Payable	Common Stock Total Equity	Common Stock
Total Assets		0.92	0.77	1.0	0.98	0.99	0.78	0.98	0.0	1.0	0.17	0.84	1.0	0.45	0.96	0.98	-0.27	1.0	0.99	0.99	0.62	0.96	0.47	0.96	-0.68	-0.69
Short Long Term Debt Total	0.92		0.6	0.92	0.87	0.88	0.95	0.86	-0.24	0.95	-0.06	0.64	0.92	0.36	0.97	0.85	-0.21	0.94	0.96	0.88	0.76	0.98	0.49	0.85	-0.52	-0.53
Other Current Liab	0.77	0.6		0.77	0.74	0.74	0.51	0.72	-0.09	0.76	0.24	0.75	0.77	0.1	0.77	0.74	-0.12	0.78	0.75	0.78	0.04	0.71	0.25	0.89	-0.33	-0.32
Total Current Liabilities	1.0	0.92	0.77		0.97	0.98	0.78	0.97	-0.02	1.0	0.2	0.82	1.0	0.46	0.96	0.98	-0.29	1.0	0.98	0.99	0.63	0.96	0.44	0.97	-0.66	-0.66
Total Stockholder Equity	0.98	0.87	0.74	0.97		0.98	0.69	1.0	0.12	0.97	0.19	0.87	0.98	0.47	0.92	0.99	-0.28	0.97	0.95	0.99	0.6	0.91	0.5	0.94	-0.78	-0.78
Property Plant And Equipment Net	0.99	0.88	0.74	0.98	0.98		0.72	0.98	0.05	0.98	0.23	0.8	0.98	0.54	0.92	0.99	-0.29	0.98	0.95	0.98	0.61	0.93	0.43	0.94	-0.73	-0.73
Net Debt	0.78	0.95	0.51	0.78	0.69	0.72		0.68	-0.51	0.83	-0.23	0.4	0.78	0.18	0.88	0.66	-0.15	0.81	0.85	0.7	0.73	0.91	0.44	0.72	-0.26	-0.27
Retained Earnings	0.98	0.86	0.72	0.97	1.0	0.98	0.68		0.14	0.96	0.2	0.87	0.98	0.49	0.9	0.99	-0.28	0.96	0.94	0.99	0.61	0.91	0.48	0.93	-0.8	-0.8
Cash	0.0	-0.24	-0.09	-0.02	0.12	0.05	-0.51	0.14		-0.07	0.46	0.35	0.01	0.47	-0.16	0.15	-0.1	-0.05	-0.1	0.1	-0.18	-0.21	0.03	-0.06	-0.63	-0.6
Non Current Assets Total	1.0	0.95	0.76	1.0	0.97	0.98	0.83	0.96	-0.07		0.13	0.79	0.99	0.44	0.97	0.97	-0.26	1.0	0.99	0.98	0.65	0.98	0.47	0.96	-0.64	-0.65
Non Currrent Assets Other	0.17	-0.06	0.24	0.2	0.19	0.23	-0.23	0.2	0.46	0.13		0.31	0.19	0.59	0.03	0.28	-0.2	0.16	0.15	0.23	-0.09	0.03	-0.06	0.23	-0.28	-0.27
Cash And Short Term Investments	0.84	0.64	0.75	0.82	0.87	0.8	0.4	0.87	0.35	0.79	0.31		0.84	0.31	0.76	0.86	-0.13	0.81	0.8	0.89	0.31	0.72	0.34	0.86	-0.71	-0.71
Net Receivables	1.0	0.92	0.77	1.0	0.98	0.98	0.78	0.98	0.01	0.99	0.19	0.84		0.46	0.96	0.98	-0.29	1.0	0.99	0.99	0.62	0.96	0.46	0.97	-0.68	-0.69
Common Stock Shares Outstanding	0.45	0.36	0.1	0.46	0.47	0.54	0.18	0.49	0.47	0.44	0.59	0.31	0.46		0.36	0.55	-0.32	0.44	0.41	0.46	0.37	0.36	0.23	0.31	-0.66	-0.66
Non Current Liabilities Total	0.96	0.97	0.77	0.96	0.92	0.92	0.88	0.9	-0.16	0.97	0.03	0.76	0.96	0.36		0.9	-0.17	0.97	0.98	0.94	0.6	0.99	0.48	0.93	-0.54	-0.55
Inventory	0.98	0.85	0.74	0.98	0.99	0.99	0.66	0.99	0.15	0.97	0.28	0.86	0.98	0.55	0.9		-0.3	0.97	0.94	0.99	0.58	0.9	0.44	0.94	-0.78	-0.78
Other Stockholder Equity	-0.27	-0.21	-0.12	-0.29	-0.28	-0.29	-0.15	-0.28	-0.1	-0.26	-0.2	-0.13	-0.29	-0.32	-0.17	-0.3		-0.26	-0.24	-0.28	-0.21	-0.22	-0.39	-0.23	0.36	0.36
Total Liab	1.0	0.94	0.78	1.0	0.97	0.98	0.81	0.96	-0.05	1.0	0.16	0.81	1.0	0.44	0.97	0.97	-0.26		0.99	0.98	0.62	0.98	0.45	0.97	-0.64	-0.64
Property Plant And Equipment Gross	0.99	0.96	0.75	0.98	0.95	0.95	0.85	0.94	-0.1	0.99	0.15	0.8	0.99	0.41	0.98	0.94	-0.24	0.99		0.97	0.66	0.99	0.49	0.95	-0.61	-0.62
Total Current Assets	0.99	0.88	0.78	0.99	0.99	0.98	0.7	0.99	0.1	0.98	0.23	0.89	0.99	0.46	0.94	0.99	-0.28	0.98	0.97		0.57	0.93	0.46	0.96	-0.73	-0.73
Short Term Debt	0.62	0.76	0.04	0.63	0.6	0.61	0.73	0.61	-0.18	0.65	-0.09	0.31	0.62	0.37	0.6	0.58	-0.21	0.62	0.66	0.57		0.69	0.37	0.47	-0.47	-0.48
Intangible Assets	0.96	0.98	0.71	0.96	0.91	0.93	0.91	0.91	-0.21	0.98	0.03	0.72	0.96	0.36	0.99	0.9	-0.22	0.98	0.99	0.93	0.69		0.49	0.92	-0.54	-0.54
Other Current Assets	0.47	0.49	0.25	0.44	0.5	0.43	0.44	0.48	0.03	0.47	-0.06	0.34	0.46	0.23	0.48	0.44	-0.39	0.45	0.49	0.46	0.37	0.49		0.4	-0.47	-0.47
Accounts Payable	0.96	0.85	0.89	0.97	0.94	0.94	0.72	0.93	-0.06	0.96	0.23	0.86	0.97	0.31	0.93	0.94	-0.23	0.97	0.95	0.96	0.47	0.92	0.4		-0.56	-0.55
Common Stock Total Equity	-0.68	-0.52	-0.33	-0.66	-0.78	-0.73	-0.26	-0.8	-0.63	-0.64	-0.28	-0.71	-0.68	-0.66	-0.54	-0.78	0.36	-0.64	-0.61	-0.73	-0.47	-0.54	-0.47	-0.56		0.99
Common Stock	-0.69	-0.53	-0.32	-0.66	-0.78	-0.73	-0.27	-0.8	-0.6	-0.65	-0.27	-0.71	-0.69	-0.66	-0.55	-0.78	0.36	-0.64	-0.62	-0.73	-0.48	-0.54	-0.47	-0.55	0.99

Click cells to compare fundamentals

Novo Nordisk Account Relationship Matchups

Novo Nordisk fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	125.6B	144.9B	194.5B	241.3B	314.5B	330.2B
Short Long Term Debt Total	4.5B	10.4B	26.6B	25.8B	27.0B	28.4B
Other Current Liab	15.8B	(24.3B)	(37.1B)	96.8B	130.5B	137.0B
Total Current Liabilities	59.0B	70.3B	99.5B	120.9B	169.7B	178.1B
Total Stockholder Equity	57.6B	63.3B	70.7B	83.5B	106.6B	111.9B
Property Plant And Equipment Net	50.6B	50.3B	55.4B	66.7B	91.0B	95.5B
Net Debt	(11.0B)	(2.4B)	15.9B	13.1B	12.6B	13.2B
Retained Earnings	57.8B	63.8B	72.0B	80.6B	104.8B	110.1B
Cash	15.5B	12.8B	10.7B	12.7B	14.4B	8.1B
Non Current Assets Total	63.2B	79.1B	108.9B	133.1B	174.8B	183.6B
Non Currrent Assets Other	841M	674M	267M	206M	21.8B	22.9B
Cash And Short Term Investments	15.5B	12.8B	17.5B	23.6B	30.2B	31.7B
Net Receivables	29.2B	32.2B	46.8B	57.5B	75.3B	79.0B
Common Stock Shares Outstanding	4.8B	4.7B	4.6B	4.5B	4.5B	3.7B
Liabilities And Stockholders Equity	125.6B	144.9B	194.5B	241.3B	314.5B	330.2B
Non Current Liabilities Total	9.0B	11.3B	24.2B	36.8B	38.3B	40.2B
Inventory	17.6B	18.5B	19.6B	24.4B	31.8B	33.4B
Total Liab	68.0B	81.6B	123.8B	157.8B	207.9B	218.3B
Property Plant And Equipment Gross	30.3B	50.3B	95.9B	111.4B	138.6B	145.5B
Total Current Assets	62.5B	65.8B	85.6B	108.2B	139.6B	146.6B
Accumulated Other Comprehensive Income	(694M)	(911M)	(1.7B)	2.4B	1.3B	1.3B
Short Term Debt	1.5B	7.5B	13.7B	1.5B	6.5B	6.8B
Intangible Assets	5.8B	20.7B	38.8B	46.3B	55.9B	58.7B
Other Current Assets	188M	2.3B	1.7B	2.7B	2.3B	1.5B
Accounts Payable	6.4B	5.7B	8.9B	15.6B	25.6B	26.9B
Common Stock Total Equity	500M	490M	480M	470M	423M	493.1M
Common Stock	480M	470M	462M	456M	451M	478.4M
Other Liab	6.0B	8.4B	11.3B	12.5B	14.4B	15.1B
Property Plant Equipment	50.6B	50.3B	55.4B	66.7B	76.7B	80.5B
Current Deferred Revenue	35.3B	38.7B	55.2B	107.6B	123.7B	129.9B
Other Assets	5.0B	6.5B	8.9B	13.4B	15.4B	16.2B
Net Tangible Assets	51.8B	42.7B	27.6B	32.1B	36.9B	37.0B
Long Term Investments	1.8B	1.6B	1.4B	1.3B	1.7B	1.5B
Short Long Term Debt	659M	6.7B	12.9B	480M	5.3B	2.9B
Long Term Debt Total	3.0B	2.9B	13.0B	24.3B	28.0B	29.4B

Pair Trading with Novo Nordisk

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Novo Nordisk position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novo Nordisk will appreciate offsetting losses from the drop in the long position's value.

Moving together with Novo Stock

0.76	ME	23Andme Holding	Pair Corr
0.88	VALN	Valneva SE ADR	Pair Corr
0.73	VCNX	Vaccinex	Pair Corr

Moving against Novo Stock

0.92	BMY	Bristol Myers Squibb Aggressive Push	Pair Corr
0.86	EWTX	Edgewise Therapeutics	Pair Corr
0.86	GILD	Gilead Sciences	Pair Corr
0.68	KZR	Kezar Life Sciences	Pair Corr
0.6	VRDN	Viridian Therapeutics	Pair Corr

The ability to find closely correlated positions to Novo Nordisk could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Novo Nordisk when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Novo Nordisk - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Novo Nordisk AS to buy it.

The correlation of Novo Nordisk is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Novo Nordisk moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Novo Nordisk AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Novo Nordisk can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Novo Nordisk AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novo Nordisk's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novo Nordisk As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novo Nordisk As Stock:

How To Invest In Novo

Details

Is Novo Stock a good investment?

Details

What is Novo Nordisk's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.224

Dividend Share

9.9

Earnings Share

2.99

Revenue Per Share

60.698

Quarterly Revenue Growth

0.214

The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Novo Research Development vs Ebit Analysis

Research Development vs Ebit

Research Development vs Ebit Correlation Analysis

Correlation Coefficient

Research Development

Ebit

Novo Nordisk fundamental ratios Correlations

Novo Nordisk Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Novo Nordisk fundamental ratios Accounts

Pair Trading with Novo Nordisk

Moving together with Novo Stock

Moving against Novo Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Liabilities	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Total Assets
Net Receivables	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Total Current Liabilities
Net Receivables	+ 1.0	Total Current Liabilities

Common Stock	- 0.8	Retained Earnings
Common Stock Total Equity	- 0.8	Retained Earnings
Common Stock	- 0.78	Inventory
Common Stock Total Equity	- 0.78	Inventory
Common Stock	- 0.78	Total Stockholder Equity
Common Stock Total Equity	- 0.78	Total Stockholder Equity